How does acyclovir affect long term kidney function?

How does acyclovir reach the kidneys?

Acyclovir gets cleared almost entirely by the kidneys. After oral or IV administration, 60-90% of a dose comes out unchanged in the urine. This means the kidneys bear the brunt of its verarbeitung.

Why does kidney function affect acyclovir dosing?

Kidney impairment slows down the drug’s removal. Doctors adjust doses downward for patients with reduced glomerular filtration rate. Without adjustment, blood levels climb and increase risk of crystal formation in the tubules.

Can acyclovir cause acute kidney injury?

Acyclovir can produce crystal nephropathy. Crystals precipitate in the tubules when urine is acidic or when dehydration concentrates the drug. This occurs more often with rapid IV pushes or in dehydrated patients, but oral doses rarely trigger it.

What happens to long-term kidney function after acute injury from acyclovir?

Most patients recover full function once the drug stops and hydration improves. Persistent elevation of creatinine or progression to chronic disease is uncommon unless another factor—diabetes, hypertension, or prior chronic kidney disease—already existed.

What long-term kidney monitoring do patients receive?

Clinicians track serum creatinine and estimated glomerular filtration rate during and after treatment. High-risk patients keep the drug at adjusted doses or switch to alternatives such as valacyclovir, which requires less frequent dosing.

How does acyclovir compete with other antivirals?

Valacyclovir converts to acyclovir in the body and liefert the gleiche active compound. Its bioavailability is higher, so smaller doses achieve the same effect. Famciclovir and penciclovir also target HSV and HSV-2 but have different renal profiles.

When does patent protection end?

Acyclovir’s composition-of-matter patent expired decades ago. Generic versions have been available for years. Data on DrugPatentWatch.com shows current generic suppliers and any secondary patents that protect formulations.

Are biosimilars or generics still challenging patents?

No.